Good afternoon!

Thanks to all who responded to my query and who sent me documents and
resources.  A summary of responses is listed below:

-- Using the search terms "comparative study" and "patient selection" with
the two types of heparin;

-- Evidence-based guidelines from guidelines.gov:  
1. Institute for Clinical Systems Improvement (ICSI). Anticoagulation
therapy 
supplement. Bloomington (MN): Institute for Clinical Systems Improvement 
(ICSI); 2005 Apr. 65 p.
<http://www.guidelines.gov/summary/summary.aspx?doc_id=7251&nbr=004313&stri
ng=unfractionated++AND+(%22low+molecular+weight%22+OR+LMWH)>
2. Institute for Clinical Systems Improvement (ICSI). Venous thromboembolism

prophylaxis. Bloomington (MN): Institute for Clinical Systems Improvement 
(ICSI); 2005 Jun. 45 p.
<http://www.guidelines.gov/summary/summary.aspx?doc_id=7617&nbr=004456&stri
ng=unfractionated+AND+%22low+molecular+weight%22>;

-- "Clinical use of heparin and low molecular weight heparin" section from
Up to Date;

-- ask the pharmacist for more details about patient characteristics (ie.
"Patients with ST-segment elevation? Or without? Non-ST-segment elevation?
Patients on consistent antithrombin therapy? Or no history of
antithrombins?");

-- 2 issues of *Pharmacist's Letter* "that summarize the evidence between
heparin versus LMWH for certain patient groups" (6/05 #210650 and 8/01
#170812).

Thanks again for all of your generous assistance!

~Christine~

Christine P. Caufield, M.L.I.S. 
Health Sciences Librarian 
Bon Secours Baltimore Health System 
(410) 362-3581 
http://www.angelfire.com/md3/bonlibrary/index.html 
*Providing quality information for quality care* 

________________________________________________________________________________________________________________________________
________________________________________________________________________________________________________________________________

The information in this communication is intended to be confidential to the Individual(s) and/or Entity to whom it is addressed.
It may contain information of a Privileged and/or Confidential nature, which is subject to Federal and/or State privacy regulations.
In the event that you are not the intended recipient or the agent of the intended recipient, do not copy or use the information
contained within this communication, or allow it to be read, copied or utilized in any manner, by any other person(s).  Should
this communication be received in error, please notify the sender immediately either by response e-mail or by phone,
and permanently delete the original e-mail, attachment(s), and any copies.